Antiplatelet Therapy in Aneurysmal Subarachnoid HemorrhageA Systematic Review
作者:
Sanne Dorhout Mees,
Gabriel Rinkel,
Jeannette Hop,
Ale Algra,
Jan van Gijn,
期刊:
Stroke: Journal of the American Heart Association
(OVID Available online 2003)
卷期:
Volume 34,
issue 9
页码: 2285-2289
ISSN:0039-2499
年代: 2003
出版商: OVID
关键词: aneurysm;antiplatelet therapy;subarachnoid hemorrhage
数据来源: OVID
摘要:
Background and Purpose—Observational studies suggest that platelet inhibitors reduce the risk of delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage and thereby have a beneficial effect on clinical outcome. Robust evidence, however, is lacking. We performed a systematic meta-analysis to determine whether antiplatelet therapy has a beneficial effect after SAH.Methods—We searched Medline and the Cochrane Library to identify all randomized controlled trials of antiplatelet drugs versus control and calculated relative risks with corresponding 95% confidence intervals (CIs) for poor outcome (dependence or death), the occurrence of DCI, and the occurrence of any intracranial hemorrhage.Results—We included 5 trials totaling 699 patients. The overall relative risk for poor outcome was 0.87 (95% CI, 0.65 to 1.17); for the occurrence of DCI (reported in 3 of the 5 studies), 0.65 (95% CI, 0.47 to 0.89); and for the occurrence of intracranial hemorrhage, 1.19 (reported in 4 of the 5 studies) (95% CI, 0.76 to 1.85).Conclusions—Our data indicate that antiplatelet drugs reduce the risk of DCI in patients with subarachnoid hemorrhage. A randomized clinical trial is warranted to assess the effect on overall outcome.
点击下载:
PDF
(64KB)
返 回